Dec 12, 2024
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial
Dec 09, 2024
Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition
Dec 03, 2024
Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept
Nov 26, 2024
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Nov 06, 2024
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Nov 06, 2024
Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
Nov 05, 2024
Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition
Oct 16, 2024
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer
Sep 12, 2024
Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference
Sep 03, 2024
Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial
Displaying 1 - 10 of 27